U.S. launch of BLOOM device funded by $4.5 million investment from Plexāā
The UK-based MedTech startup, Plexāā, has announced a funding extension of 4.5 million USD for the U.S. launch of their groundbreaking medical device, BLOOM43, and future innovations. This device, designed to reduce complication rates in breast surgeries, is set to revolutionise the surgical landscape.
BLOOM43 employs a unique technique called Supraphysiological Preconditioning, which thermally preconditions the skin to enhance blood flow and promote wound healing. This method, shown effective in reducing wound healing complications in proof-of-concept clinical trials, triggers the release of heat-shock proteins to improve the overall surgical experience.
One of the key features of BLOOM43 is its wearable design, making it the world's first fully wearable device for this purpose. This user-friendly design ensures accessibility for patients preparing for breast cancer surgery and reconstruction. The device is accompanied by a companion app, which enhances patient experience and surgical readiness through holistic prehabilitation and preconditioning.
Plexāā's team brings together clinical, engineering, and operational expertise from some of the UK's leading institutions. The founder and CEO, Dr. Saahil Mehta, expressed gratitude for the team's progress and the funding's validation of their technology and Supraphysiological Preconditioning concept.
THENA Capital, a venture capital firm that champions UK MedTech leadership teams, is well-suited to help Plexāā expand into women's health and adjacent categories. Tatum Getty, founding General Partner at THENA Capital, has expressed excitement about Plexāā becoming the first portfolio company for THENA Capital's Fund I.
Plexāā's mission is to solve a critical and under-addressed challenge across the surgical pathway: reducing post-operative complications for patients, which also addresses the impact on both providers and payers. The startup aims to collaborate with clinicians, patients, and partners worldwide to make prehabilitation and preconditioning the standard of care for surgery.
With the imminent commercial launch in the U.S. and multiple partners secured for the launch, Plexāā plans to deliver transformative solutions that address unmet needs in surgical care. The BLOOM43 medical device offers a beacon of hope for patients undergoing breast surgery, promising to improve outcomes and enhance the overall surgical experience.
- The unique Supraphysiological Preconditioning technique, demonstrated effective in reducing wound healing complications during clinical trials, is a key component of Plexāā's groundbreaking medical device, BLOOM43.
- As digitization becomes increasingly important in healthcare, Plexāā's companion app, designed to enhance patient experience and readiness through prehabilitation and preconditioning, exemplifies the intersection of digital health and femtech news.
- In the quest to revolutionize medical-conditions management and improve health-and-wellness outcomes, Plexāā's mission extends beyond breast surgeries to collaborate with global partners and establish prehabilitation and preconditioning as the standard of care for surgery.
